Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by retiredcopon Nov 16, 2021 4:45pm
306 Views
Post# 34133745

These guys just have money to burn!!

These guys just have money to burn!!

The Pittsburgh Penguins appear poised for a change in ownership.

Sportico reports Fenway Sports Group is finalizing a deal to purchase the team from Mario Lemieux and Ronald Burkle.

Fenway Sports Group, headed by John Henry and Tom Werner, is the parent company of both the Boston Red Sox and Liverpool. Los Angeles Lakers superstar LeBron James is also a partner.

The Pens have been owned by franchise icon Lemieux and Burkle since 1999 when the pair bought the team out of bankruptcy.

According to Sportico's most recent franchise valuations released in October, the Penguins are the 15th most valuable franchise in the NHL and are worth approximately $840 million.

The Penguins have won three Stanley Cups since 2009 and five in total.

<< Previous
Bullboard Posts
Next >>